Shares of Bruker Corporation (Nasdaq: BRKR) were down sharply in early trade on Friday, retreating around 10% to 14% after the scientific instruments maker reported fourth-quarter earnings that missed analyst expectations. The stock has traded in a wide range over the past 52 weeks, with a high near $45 and a low around $32, and recent weakness reflects pressure in capital equipment and research spending.
For the quarter ended December 31, 2025, Bruker reported revenues of $977.2 million, roughly flat compared with $979.6 million in the year-ago period. On an organic basis, revenues declined approximately 5.1% year-over-year as academic funding and research budgets remained constrained.
Adjusted earnings per share of $0.59 fell short of the consensus forecast near $0.65 and declined about 22% from $0.76 a year earlier. The company also reported a GAAP diluted EPS of $0.10, marginally above $0.09 in the prior year. The earnings miss was cited by traders as a key driver for the share drop.
Bruker’s non-GAAP operating margin compressed to about 15.7% from 18.1% in the prior year, reflecting continued cost pressures from tariffs, currency and mix, and volume weakness across key businesses. Organic revenue declines were reported in both its Scientific Instruments and Energy & Super Technologies segments.
For fiscal 2025, Bruker posted revenues of $3.44 billion, up approximately 2.1% year-over-year, although organic revenue fell near 3.7% after stripping out acquisitions and currency effects. Non-GAAP diluted EPS of $1.83 lagged the $2.41 posted in 2024. On a GAAP basis, the company reported a net loss of $(0.15) per share, compared with EPS of $0.76 in the prior year. Margins for the full year also contracted, pressured by lower volume and restructuring charges recorded earlier in the year.
Bruker noted that growth contributions from acquisitions and foreign exchange provided modest top-line support in both the quarter and full year, but organic demand in core research and industrial markets remained subdued. Book-to-bill ratios in the Scientific Instruments business remained above 1.0 in the quarter, indicating some improvement in order patterns.
The company provided guidance for fiscal 2026, targeting revenues of $3.57 billion to $3.60 billion, representing about 4% to 5% reported year-over-year growth, with 1% to 2% organic growth and contributions from acquisitions and currency tailwinds. It forecasts non-GAAP EPS of $2.10 to $2.15, roughly 15% to 17% above 2025’s results, though subject to a projected foreign exchange headwind.
Management highlighted ongoing cost-saving initiatives aimed at expanding margins and driving double-digit earnings growth in 2026. The company also noted expectations of improved demand in biopharma, industrial research, and semiconductor end markets later in the year.
Bruker’s results come amid broader headwinds in scientific instrumentation and research-oriented capital equipment, where funding constraints, tight university budgets, and fluctuating industrial research spending have weighed on bookings. These macro pressures have also affected parts of the software and SaaS sector tied to scientific computing and data analytics, where discretionary research and enterprise IT investments have slowed.
Software and SaaS stocks have faced similar challenges, with slower organic growth and margin compression reported by several companies as customers delay non-critical projects and renewals in response to higher interest rates and uncertain economic conditions.
The stock’s sharp decline reflects investor disappointment with the earnings per share miss and margin contraction, despite revenue roughly in line with forecasts. The wider trading range over the past year underscores ongoing volatility for capital-intensive technology names in the current macro environment.
